MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ
3.970
-0.220
-5.25%
Closed 19:46 11/12 EST
OPEN
4.140
PREV CLOSE
4.190
HIGH
4.180
LOW
3.870
VOLUME
4.47M
TURNOVER
0
52 WEEK HIGH
7.18
52 WEEK LOW
2.540
MARKET CAP
757.33M
P/E (TTM)
-3.4612
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Schrodinger (SDGR) and Hims & Hers Health (HIMS)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Larimar Therapeutics (LRMR) and AbCellera Biologics (ABCL)
TipRanks · 2d ago
Wells Fargo Remains a Buy on Annexon Biosciences (ANNX)
TipRanks · 2d ago
Annexon Biosciences (ANNX) Receives a Buy from Bank of America Securities
TipRanks · 2d ago
Annexon, Inc. Reports Third Quarter 2026 Financial Results and Strategic Credit Facility of up to $200 million
NASDAQ · 3d ago
Annexon Biosciences GAAP EPS of -$0.25
Seeking Alpha · 3d ago
Annexon Q3 EPS $(0.25) Beats $(0.28) Estimate
Benzinga · 3d ago
Annexon reports Q3 EPS (25c), consensus (28c)
TipRanks · 3d ago
More
About ANNX
Annexon, Inc. is a biopharmaceutical company advancing targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Tanruprubart is an investigational-targeted immunotherapy delivered in a single infusion to rapidly halt aggressive neuroinflammation and damage in GBS, an acute, rare, neuromuscular emergency. The Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness. ANX1502, a novel oral small molecule for autoimmune conditions. The Company's next wave programs include ANX005 and ANX009. ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis.

Webull offers Annexon Inc stock information, including NASDAQ: ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.